1 Study Coverage
    1.1 Tumor Necrosis Factor Receptor Superfamily Member 1A Product Introduction
    1.2 Market by Type
        1.2.1 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
        1.2.2 LY-3232094
        1.2.3 EYS-606
        1.2.4 SRT-100
        1.2.5 Others
    1.3 Market by Application
        1.3.1 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
        1.3.2 Genital Warts
        1.3.3 Melanoma
        1.3.4 Multiple Sclerosis
        1.3.5 Psoriasis
        1.3.6 Others
    1.4 Study Objectives
    1.5 Years Considered
2 Executive Summary
    2.1 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Estimates and Forecasts 2017-2028
    2.2 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Estimates and Forecasts 2017-2028
    2.3 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Region: 2017 VS 2021 VS 2028
    2.4 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Region
        2.4.1 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Region (2017-2022)
        2.4.2 Global Sales Tumor Necrosis Factor Receptor Superfamily Member 1A by Region (2023-2028)
    2.5 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Region
        2.5.1 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Region (2017-2022)
        2.5.2 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Region (2023-2028)
    2.6 North America
    2.7 Europe
    2.8 Asia-Pacific
    2.9 Latin America
    2.10 Middle East & Africa
3 Competition by Manufacturers
    3.1 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Manufacturers
        3.1.1 Global Top Tumor Necrosis Factor Receptor Superfamily Member 1A Manufacturers by Sales (2017-2022)
        3.1.2 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Market Share by Manufacturers (2017-2022)
        3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Tumor Necrosis Factor Receptor Superfamily Member 1A in 2021
    3.2 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Manufacturers
        3.2.1 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Manufacturers (2017-2022)
        3.2.2 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Market Share by Manufacturers (2017-2022)
        3.2.3 Global Top 10 and Top 5 Companies by Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue in 2021
    3.3 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Price by Manufacturers (2017-2022)
    3.4 Analysis of Competitive Landscape
        3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
        3.4.3 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Manufacturers Geographical Distribution
    3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
    4.1 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Type
        4.1.1 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Historical Sales by Type (2017-2022)
        4.1.2 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Forecasted Sales by Type (2023-2028)
        4.1.3 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Market Share by Type (2017-2028)
    4.2 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Type
        4.2.1 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Historical Revenue by Type (2017-2022)
        4.2.2 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Forecasted Revenue by Type (2023-2028)
        4.2.3 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Market Share by Type (2017-2028)
    4.3 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Price by Type
        4.3.1 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Price by Type (2017-2022)
        4.3.2 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Price Forecast by Type (2023-2028)
5 Market Size by Application
    5.1 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Application
        5.1.1 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Historical Sales by Application (2017-2022)
        5.1.2 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Forecasted Sales by Application (2023-2028)
        5.1.3 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Market Share by Application (2017-2028)
    5.2 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Application
        5.2.1 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Historical Revenue by Application (2017-2022)
        5.2.2 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Forecasted Revenue by Application (2023-2028)
        5.2.3 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Market Share by Application (2017-2028)
    5.3 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Price by Application
        5.3.1 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Price by Application (2017-2022)
        5.3.2 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Price Forecast by Application (2023-2028)
6 North America
    6.1 North America Tumor Necrosis Factor Receptor Superfamily Member 1A Market Size by Type
        6.1.1 North America Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Type (2017-2028)
        6.1.2 North America Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Type (2017-2028)
    6.2 North America Tumor Necrosis Factor Receptor Superfamily Member 1A Market Size by Application
        6.2.1 North America Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Application (2017-2028)
        6.2.2 North America Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Application (2017-2028)
    6.3 North America Tumor Necrosis Factor Receptor Superfamily Member 1A Market Size by Country
        6.3.1 North America Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Country (2017-2028)
        6.3.2 North America Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Country (2017-2028)
        6.3.3 U.S.
        6.3.4 Canada
7 Europe
    7.1 Europe Tumor Necrosis Factor Receptor Superfamily Member 1A Market Size by Type
        7.1.1 Europe Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Type (2017-2028)
        7.1.2 Europe Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Type (2017-2028)
    7.2 Europe Tumor Necrosis Factor Receptor Superfamily Member 1A Market Size by Application
        7.2.1 Europe Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Application (2017-2028)
        7.2.2 Europe Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Application (2017-2028)
    7.3 Europe Tumor Necrosis Factor Receptor Superfamily Member 1A Market Size by Country
        7.3.1 Europe Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Country (2017-2028)
        7.3.2 Europe Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Country (2017-2028)
        7.3.3 Germany
        7.3.4 France
        7.3.5 U.K.
        7.3.6 Italy
        7.3.7 Russia
8 Asia Pacific
    8.1 Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 1A Market Size by Type
        8.1.1 Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Type (2017-2028)
        8.1.2 Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Type (2017-2028)
    8.2 Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 1A Market Size by Application
        8.2.1 Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Application (2017-2028)
        8.2.2 Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Application (2017-2028)
    8.3 Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 1A Market Size by Region
        8.3.1 Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Region (2017-2028)
        8.3.2 Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Region (2017-2028)
        8.3.3 China
        8.3.4 Japan
        8.3.5 South Korea
        8.3.6 India
        8.3.7 Australia
        8.3.8 Taiwan
        8.3.9 Indonesia
        8.3.10 Thailand
        8.3.11 Malaysia
        8.3.12 Philippines
9 Latin America
    9.1 Latin America Tumor Necrosis Factor Receptor Superfamily Member 1A Market Size by Type
        9.1.1 Latin America Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Type (2017-2028)
        9.1.2 Latin America Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Type (2017-2028)
    9.2 Latin America Tumor Necrosis Factor Receptor Superfamily Member 1A Market Size by Application
        9.2.1 Latin America Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Application (2017-2028)
        9.2.2 Latin America Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Application (2017-2028)
    9.3 Latin America Tumor Necrosis Factor Receptor Superfamily Member 1A Market Size by Country
        9.3.1 Latin America Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Country (2017-2028)
        9.3.2 Latin America Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Country (2017-2028)
        9.3.3 Mexico
        9.3.4 Brazil
        9.3.5 Argentina
10 Middle East and Africa
    10.1 Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Member 1A Market Size by Type
        10.1.1 Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Type (2017-2028)
        10.1.2 Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Type (2017-2028)
    10.2 Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Member 1A Market Size by Application
        10.2.1 Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Application (2017-2028)
        10.2.2 Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Application (2017-2028)
    10.3 Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Member 1A Market Size by Country
        10.3.1 Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Country (2017-2028)
        10.3.2 Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Country (2017-2028)
        10.3.3 Turkey
        10.3.4 Saudi Arabia
11 Company Profiles
    11.1 Addex Therapeutics Ltd
        11.1.1 Addex Therapeutics Ltd Corporation Information
        11.1.2 Addex Therapeutics Ltd Overview
        11.1.3 Addex Therapeutics Ltd Tumor Necrosis Factor Receptor Superfamily Member 1A Sales, Price, Revenue and Gross Margin (2017-2022)
        11.1.4 Addex Therapeutics Ltd Tumor Necrosis Factor Receptor Superfamily Member 1A Product Model Numbers, Pictures, Descriptions and Specifications
        11.1.5 Addex Therapeutics Ltd Recent Developments
    11.2 G&E Herbal Biotechnology Co., Ltd.
        11.2.1 G&E Herbal Biotechnology Co., Ltd. Corporation Information
        11.2.2 G&E Herbal Biotechnology Co., Ltd. Overview
        11.2.3 G&E Herbal Biotechnology Co., Ltd. Tumor Necrosis Factor Receptor Superfamily Member 1A Sales, Price, Revenue and Gross Margin (2017-2022)
        11.2.4 G&E Herbal Biotechnology Co., Ltd. Tumor Necrosis Factor Receptor Superfamily Member 1A Product Model Numbers, Pictures, Descriptions and Specifications
        11.2.5 G&E Herbal Biotechnology Co., Ltd. Recent Developments
    11.3 GlaxoSmithKline Plc
        11.3.1 GlaxoSmithKline Plc Corporation Information
        11.3.2 GlaxoSmithKline Plc Overview
        11.3.3 GlaxoSmithKline Plc Tumor Necrosis Factor Receptor Superfamily Member 1A Sales, Price, Revenue and Gross Margin (2017-2022)
        11.3.4 GlaxoSmithKline Plc Tumor Necrosis Factor Receptor Superfamily Member 1A Product Model Numbers, Pictures, Descriptions and Specifications
        11.3.5 GlaxoSmithKline Plc Recent Developments
    11.4 Inflamalps SA
        11.4.1 Inflamalps SA Corporation Information
        11.4.2 Inflamalps SA Overview
        11.4.3 Inflamalps SA Tumor Necrosis Factor Receptor Superfamily Member 1A Sales, Price, Revenue and Gross Margin (2017-2022)
        11.4.4 Inflamalps SA Tumor Necrosis Factor Receptor Superfamily Member 1A Product Model Numbers, Pictures, Descriptions and Specifications
        11.4.5 Inflamalps SA Recent Developments
    11.5 Polaris Pharmaceuticals, Inc.
        11.5.1 Polaris Pharmaceuticals, Inc. Corporation Information
        11.5.2 Polaris Pharmaceuticals, Inc. Overview
        11.5.3 Polaris Pharmaceuticals, Inc. Tumor Necrosis Factor Receptor Superfamily Member 1A Sales, Price, Revenue and Gross Margin (2017-2022)
        11.5.4 Polaris Pharmaceuticals, Inc. Tumor Necrosis Factor Receptor Superfamily Member 1A Product Model Numbers, Pictures, Descriptions and Specifications
        11.5.5 Polaris Pharmaceuticals, Inc. Recent Developments
12 Industry Chain and Sales Channels Analysis
    12.1 Tumor Necrosis Factor Receptor Superfamily Member 1A Industry Chain Analysis
    12.2 Tumor Necrosis Factor Receptor Superfamily Member 1A Key Raw Materials
        12.2.1 Key Raw Materials
        12.2.2 Raw Materials Key Suppliers
    12.3 Tumor Necrosis Factor Receptor Superfamily Member 1A Production Mode & Process
    12.4 Tumor Necrosis Factor Receptor Superfamily Member 1A Sales and Marketing
        12.4.1 Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Channels
        12.4.2 Tumor Necrosis Factor Receptor Superfamily Member 1A Distributors
    12.5 Tumor Necrosis Factor Receptor Superfamily Member 1A Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
    13.1 Tumor Necrosis Factor Receptor Superfamily Member 1A Industry Trends
    13.2 Tumor Necrosis Factor Receptor Superfamily Member 1A Market Drivers
    13.3 Tumor Necrosis Factor Receptor Superfamily Member 1A Market Challenges
    13.4 Tumor Necrosis Factor Receptor Superfamily Member 1A Market Restraints
14 Key Findings in The Global Tumor Necrosis Factor Receptor Superfamily Member 1A Study
15 Appendix
    15.1 Research Methodology
        15.1.1 Methodology/Research Approach
        15.1.2 Data Source
    15.2 Author Details
    15.3 Disclaimer
                  
              

                

                 
List of Tables
    Table 1. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
    Table 2. Major Manufacturers of LY-3232094
    Table 3. Major Manufacturers of EYS-606
    Table 4. Major Manufacturers of SRT-100
    Table 5. Major Manufacturers of Others
    Table 6. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
    Table 7. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
    Table 8. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Region (2017-2022) & (K Units)
    Table 9. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Market Share by Region (2017-2022)
    Table 10. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Region (2023-2028) & (K Units)
    Table 11. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Market Share by Region (2023-2028)
    Table 12. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Region (2017-2022) & (US$ Million)
    Table 13. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Market Share by Region (2017-2022)
    Table 14. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Region (2023-2028) & (US$ Million)
    Table 15. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Market Share by Region (2023-2028)
    Table 16. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Manufacturers (2017-2022) & (K Units)
    Table 17. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Share by Manufacturers (2017-2022)
    Table 18. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Manufacturers (2017-2022) & (US$ Million)
    Table 19. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Share by Manufacturers (2017-2022)
    Table 20. Tumor Necrosis Factor Receptor Superfamily Member 1A Price by Manufacturers (2017-2022) &(USD/Unit)
    Table 21. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 22. Global Tumor Necrosis Factor Receptor Superfamily Member 1A by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tumor Necrosis Factor Receptor Superfamily Member 1A as of 2021)
    Table 23. Tumor Necrosis Factor Receptor Superfamily Member 1A Manufacturing Base Distribution and Headquarters
    Table 24. Manufacturers Tumor Necrosis Factor Receptor Superfamily Member 1A Product Offered
    Table 25. Date of Manufacturers Enter into Tumor Necrosis Factor Receptor Superfamily Member 1A Market
    Table 26. Mergers & Acquisitions, Expansion Plans
    Table 27. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Type (2017-2022) & (K Units)
    Table 28. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Type (2023-2028) & (K Units)
    Table 29. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Share by Type (2017-2022)
    Table 30. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Share by Type (2023-2028)
    Table 31. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Type (2017-2022) & (US$ Million)
    Table 32. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Type (2023-2028) & (US$ Million)
    Table 33. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Share by Type (2017-2022)
    Table 34. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Share by Type (2023-2028)
    Table 35. Tumor Necrosis Factor Receptor Superfamily Member 1A Price by Type (2017-2022) & (USD/Unit)
    Table 36. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Price Forecast by Type (2023-2028) & (USD/Unit)
    Table 37. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Application (2017-2022) & (K Units)
    Table 38. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Application (2023-2028) & (K Units)
    Table 39. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Share by Application (2017-2022)
    Table 40. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Share by Application (2023-2028)
    Table 41. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Application (2017-2022) & (US$ Million)
    Table 42. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Application (2023-2028) & (US$ Million)
    Table 43. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Share by Application (2017-2022)
    Table 44. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Share by Application (2023-2028)
    Table 45. Tumor Necrosis Factor Receptor Superfamily Member 1A Price by Application (2017-2022) & (USD/Unit)
    Table 46. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Price Forecast by Application (2023-2028) & (USD/Unit)
    Table 47. North America Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Type (2017-2022) & (K Units)
    Table 48. North America Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Type (2023-2028) & (K Units)
    Table 49. North America Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Type (2017-2022) & (US$ Million)
    Table 50. North America Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Type (2023-2028) & (US$ Million)
    Table 51. North America Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Application (2017-2022) & (K Units)
    Table 52. North America Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Application (2023-2028) & (K Units)
    Table 53. North America Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Application (2017-2022) & (US$ Million)
    Table 54. North America Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Application (2023-2028) & (US$ Million)
    Table 55. North America Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Country (2017-2022) & (K Units)
    Table 56. North America Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Country (2023-2028) & (K Units)
    Table 57. North America Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Country (2017-2022) & (US$ Million)
    Table 58. North America Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Country (2023-2028) & (US$ Million)
    Table 59. Europe Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Type (2017-2022) & (K Units)
    Table 60. Europe Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Type (2023-2028) & (K Units)
    Table 61. Europe Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Type (2017-2022) & (US$ Million)
    Table 62. Europe Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Type (2023-2028) & (US$ Million)
    Table 63. Europe Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Application (2017-2022) & (K Units)
    Table 64. Europe Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Application (2023-2028) & (K Units)
    Table 65. Europe Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Application (2017-2022) & (US$ Million)
    Table 66. Europe Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Application (2023-2028) & (US$ Million)
    Table 67. Europe Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Country (2017-2022) & (K Units)
    Table 68. Europe Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Country (2023-2028) & (K Units)
    Table 69. Europe Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Country (2017-2022) & (US$ Million)
    Table 70. Europe Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Country (2023-2028) & (US$ Million)
    Table 71. Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Type (2017-2022) & (K Units)
    Table 72. Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Type (2023-2028) & (K Units)
    Table 73. Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Type (2017-2022) & (US$ Million)
    Table 74. Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Type (2023-2028) & (US$ Million)
    Table 75. Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Application (2017-2022) & (K Units)
    Table 76. Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Application (2023-2028) & (K Units)
    Table 77. Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Application (2017-2022) & (US$ Million)
    Table 78. Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Application (2023-2028) & (US$ Million)
    Table 79. Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Region (2017-2022) & (K Units)
    Table 80. Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Region (2023-2028) & (K Units)
    Table 81. Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Region (2017-2022) & (US$ Million)
    Table 82. Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Region (2023-2028) & (US$ Million)
    Table 83. Latin America Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Type (2017-2022) & (K Units)
    Table 84. Latin America Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Type (2023-2028) & (K Units)
    Table 85. Latin America Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Type (2017-2022) & (US$ Million)
    Table 86. Latin America Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Type (2023-2028) & (US$ Million)
    Table 87. Latin America Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Application (2017-2022) & (K Units)
    Table 88. Latin America Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Application (2023-2028) & (K Units)
    Table 89. Latin America Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Application (2017-2022) & (US$ Million)
    Table 90. Latin America Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Application (2023-2028) & (US$ Million)
    Table 91. Latin America Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Country (2017-2022) & (K Units)
    Table 92. Latin America Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Country (2023-2028) & (K Units)
    Table 93. Latin America Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Country (2017-2022) & (US$ Million)
    Table 94. Latin America Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Country (2023-2028) & (US$ Million)
    Table 95. Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Type (2017-2022) & (K Units)
    Table 96. Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Type (2023-2028) & (K Units)
    Table 97. Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Type (2017-2022) & (US$ Million)
    Table 98. Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Type (2023-2028) & (US$ Million)
    Table 99. Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Application (2017-2022) & (K Units)
    Table 100. Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Application (2023-2028) & (K Units)
    Table 101. Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Application (2017-2022) & (US$ Million)
    Table 102. Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Application (2023-2028) & (US$ Million)
    Table 103. Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Country (2017-2022) & (K Units)
    Table 104. Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Country (2023-2028) & (K Units)
    Table 105. Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Country (2017-2022) & (US$ Million)
    Table 106. Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Country (2023-2028) & (US$ Million)
    Table 107. Addex Therapeutics Ltd Corporation Information
    Table 108. Addex Therapeutics Ltd Description and Major Businesses
    Table 109. Addex Therapeutics Ltd Tumor Necrosis Factor Receptor Superfamily Member 1A Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 110. Addex Therapeutics Ltd Tumor Necrosis Factor Receptor Superfamily Member 1A Product Model Numbers, Pictures, Descriptions and Specifications
    Table 111. Addex Therapeutics Ltd Recent Developments
    Table 112. G&E Herbal Biotechnology Co., Ltd. Corporation Information
    Table 113. G&E Herbal Biotechnology Co., Ltd. Description and Major Businesses
    Table 114. G&E Herbal Biotechnology Co., Ltd. Tumor Necrosis Factor Receptor Superfamily Member 1A Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 115. G&E Herbal Biotechnology Co., Ltd. Tumor Necrosis Factor Receptor Superfamily Member 1A Product Model Numbers, Pictures, Descriptions and Specifications
    Table 116. G&E Herbal Biotechnology Co., Ltd. Recent Developments
    Table 117. GlaxoSmithKline Plc Corporation Information
    Table 118. GlaxoSmithKline Plc Description and Major Businesses
    Table 119. GlaxoSmithKline Plc Tumor Necrosis Factor Receptor Superfamily Member 1A Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 120. GlaxoSmithKline Plc Tumor Necrosis Factor Receptor Superfamily Member 1A Product Model Numbers, Pictures, Descriptions and Specifications
    Table 121. GlaxoSmithKline Plc Recent Developments
    Table 122. Inflamalps SA Corporation Information
    Table 123. Inflamalps SA Description and Major Businesses
    Table 124. Inflamalps SA Tumor Necrosis Factor Receptor Superfamily Member 1A Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 125. Inflamalps SA Tumor Necrosis Factor Receptor Superfamily Member 1A Product Model Numbers, Pictures, Descriptions and Specifications
    Table 126. Inflamalps SA Recent Developments
    Table 127. Polaris Pharmaceuticals, Inc. Corporation Information
    Table 128. Polaris Pharmaceuticals, Inc. Description and Major Businesses
    Table 129. Polaris Pharmaceuticals, Inc. Tumor Necrosis Factor Receptor Superfamily Member 1A Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 130. Polaris Pharmaceuticals, Inc. Tumor Necrosis Factor Receptor Superfamily Member 1A Product Model Numbers, Pictures, Descriptions and Specifications
    Table 131. Polaris Pharmaceuticals, Inc. Recent Developments
    Table 132. Key Raw Materials Lists
    Table 133. Raw Materials Key Suppliers Lists
    Table 134. Tumor Necrosis Factor Receptor Superfamily Member 1A Distributors List
    Table 135. Tumor Necrosis Factor Receptor Superfamily Member 1A Customers List
    Table 136. Tumor Necrosis Factor Receptor Superfamily Member 1A Market Trends
    Table 137. Tumor Necrosis Factor Receptor Superfamily Member 1A Market Drivers
    Table 138. Tumor Necrosis Factor Receptor Superfamily Member 1A Market Challenges
    Table 139. Tumor Necrosis Factor Receptor Superfamily Member 1A Market Restraints
    Table 140. Research Programs/Design for This Report
    Table 141. Key Data Information from Secondary Sources
    Table 142. Key Data Information from Primary Sources
List of Figures
    Figure 1. Tumor Necrosis Factor Receptor Superfamily Member 1A Product Picture
    Figure 3. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Market Share by Type in 2021 & 2028
    Figure 3. LY-3232094 Product Picture
    Figure 4. EYS-606 Product Picture
    Figure 5. SRT-100 Product Picture
    Figure 6. Others Product Picture
    Figure 7. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Market Share by Application in 2021 & 2028
    Figure 8. Genital Warts
    Figure 9. Melanoma
    Figure 10. Multiple Sclerosis
    Figure 11. Psoriasis
    Figure 12. Others
    Figure 13. Tumor Necrosis Factor Receptor Superfamily Member 1A Report Years Considered
    Figure 14. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales 2017-2028 (K Units)
    Figure 15. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue, (US$ Million), 2017 VS 2021 VS 2028
    Figure 16. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue 2017-2028 (US$ Million)
    Figure 17. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Market Share by Region in Percentage: 2021 Versus 2028
    Figure 18. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Market Share by Region (2017-2022)
    Figure 19. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Market Share by Region (2023-2028)
    Figure 20. North America Tumor Necrosis Factor Receptor Superfamily Member 1A Sales YoY (2017-2028) & (K Units)
    Figure 21. North America Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue YoY (2017-2028) & (US$ Million)
    Figure 22. Europe Tumor Necrosis Factor Receptor Superfamily Member 1A Sales YoY (2017-2028) & (K Units)
    Figure 23. Europe Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue YoY (2017-2028) & (US$ Million)
    Figure 24. Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 1A Sales YoY (2017-2028) & (K Units)
    Figure 25. Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue YoY (2017-2028) & (US$ Million)
    Figure 26. Latin America Tumor Necrosis Factor Receptor Superfamily Member 1A Sales YoY (2017-2028) & (K Units)
    Figure 27. Latin America Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue YoY (2017-2028) & (US$ Million)
    Figure 28. Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 1A Sales YoY (2017-2028) & (K Units)
    Figure 29. Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue YoY (2017-2028) & (US$ Million)
    Figure 30. The Tumor Necrosis Factor Receptor Superfamily Member 1A Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
    Figure 31. The Top 5 and 10 Largest Manufacturers of Tumor Necrosis Factor Receptor Superfamily Member 1A in the World: Market Share by Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue in 2021
    Figure 32. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
    Figure 33. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Market Share by Type (2017-2028)
    Figure 34. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Market Share by Type (2017-2028)
    Figure 35. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Market Share by Application (2017-2028)
    Figure 36. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Market Share by Application (2017-2028)
    Figure 37. North America Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Market Share by Type (2017-2028)
    Figure 38. North America Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Market Share by Type (2017-2028)
    Figure 39. North America Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Market Share by Application (2017-2028)
    Figure 40. North America Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Market Share by Application (2017-2028)
    Figure 41. North America Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Share by Country (2017-2028)
    Figure 42. North America Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Share by Country (2017-2028)
    Figure 43. U.S. Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue (2017-2028) & (US$ Million)
    Figure 44. Canada Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue (2017-2028) & (US$ Million)
    Figure 45. Europe Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Market Share by Type (2017-2028)
    Figure 46. Europe Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Market Share by Type (2017-2028)
    Figure 47. Europe Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Market Share by Application (2017-2028)
    Figure 48. Europe Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Market Share by Application (2017-2028)
    Figure 49. Europe Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Share by Country (2017-2028)
    Figure 50. Europe Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Share by Country (2017-2028)
    Figure 51. Germany Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue (2017-2028) & (US$ Million)
    Figure 52. France Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue (2017-2028) & (US$ Million)
    Figure 53. U.K. Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue (2017-2028) & (US$ Million)
    Figure 54. Italy Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue (2017-2028) & (US$ Million)
    Figure 55. Russia Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue (2017-2028) & (US$ Million)
    Figure 56. Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Market Share by Type (2017-2028)
    Figure 57. Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Market Share by Type (2017-2028)
    Figure 58. Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Market Share by Application (2017-2028)
    Figure 59. Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Market Share by Application (2017-2028)
    Figure 60. Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Share by Region (2017-2028)
    Figure 61. Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Share by Region (2017-2028)
    Figure 62. China Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue (2017-2028) & (US$ Million)
    Figure 63. Japan Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue (2017-2028) & (US$ Million)
    Figure 64. South Korea Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue (2017-2028) & (US$ Million)
    Figure 65. India Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue (2017-2028) & (US$ Million)
    Figure 66. Australia Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue (2017-2028) & (US$ Million)
    Figure 67. Taiwan Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue (2017-2028) & (US$ Million)
    Figure 68. Indonesia Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue (2017-2028) & (US$ Million)
    Figure 69. Thailand Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue (2017-2028) & (US$ Million)
    Figure 70. Malaysia Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue (2017-2028) & (US$ Million)
    Figure 71. Philippines Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue (2017-2028) & (US$ Million)
    Figure 72. Latin America Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Market Share by Type (2017-2028)
    Figure 73. Latin America Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Market Share by Type (2017-2028)
    Figure 74. Latin America Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Market Share by Application (2017-2028)
    Figure 75. Latin America Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Market Share by Application (2017-2028)
    Figure 76. Latin America Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Share by Country (2017-2028)
    Figure 77. Latin America Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Share by Country (2017-2028)
    Figure 78. Mexico Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue (2017-2028) & (US$ Million)
    Figure 79. Brazil Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue (2017-2028) & (US$ Million)
    Figure 80. Argentina Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue (2017-2028) & (US$ Million)
    Figure 81. Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Market Share by Type (2017-2028)
    Figure 82. Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Market Share by Type (2017-2028)
    Figure 83. Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Market Share by Application (2017-2028)
    Figure 84. Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Market Share by Application (2017-2028)
    Figure 85. Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Share by Country (2017-2028)
    Figure 86. Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Share by Country (2017-2028)
    Figure 87. Turkey Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue (2017-2028) & (US$ Million)
    Figure 88. Saudi Arabia Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue (2017-2028) & (US$ Million)
    Figure 89. U.A.E Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue (2017-2028) & (US$ Million)
    Figure 90. Tumor Necrosis Factor Receptor Superfamily Member 1A Value Chain
    Figure 91. Tumor Necrosis Factor Receptor Superfamily Member 1A Production Process
    Figure 92. Channels of Distribution
    Figure 93. Distributors Profiles
    Figure 94. Bottom-up and Top-down Approaches for This Report
    Figure 95. Data Triangulation
    Figure 96. Key Executives Interviewed